WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · LC 1976

Legislative bill overview

Bill LC 1976 would establish a pilot program in Montana to study the therapeutic use of psilocybin (a psychoactive compound found in certain mushrooms) under medical supervision for treating specific mental health conditions. The bill would create a regulated framework allowing licensed healthcare providers to administer psilocybin-assisted therapy to patients in controlled clinical settings.

Why is this important

This bill reflects growing scientific interest in psychedelic-assisted psychotherapy, with recent research suggesting potential benefits for treatment-resistant depression, PTSD, and end-of-life anxiety. If enacted, it could position Montana as an early adopter of emerging mental health treatments while generating data on safety and efficacy in a controlled environment, potentially influencing similar efforts nationwide.

Potential points of contention

  • Federal legal conflict: Psilocybin remains a Schedule I controlled substance under federal law, creating tension with state authorization and complicating interstate research and practitioner licensing
  • Safety and liability concerns: Questions about long-term effects, appropriate patient screening, dosing protocols, and who bears responsibility if adverse psychiatric outcomes occur
  • Research ethics and accessibility: Debate over who qualifies for the pilot program, whether it prioritizes rigorous science versus patient access, and concerns about equitable distribution of a potentially limited therapy resource

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.